Experimental eye drops help blind mice see again
Researchers have developed a new class of light-responsive drugs that can restore visual function in animal models of blindness. These photoswitchable compounds aim to bypass damaged photoreceptors by activating remaining retinal circuitry.
Why it matters
This approach offers a potentially less invasive and more accessible alternative to current gene therapies or electronic implants for treating blindness.
Photoreceptor degeneration is behind several major causes of blindness, including age-related macular degeneration (AMD) and retinitis pigmentosa (RP). Together, these disorders affect about 200 million people worldwide and rank among the leading causes of visual impairment and blindness. Beyond the profound effects on independence and quality of life, vision loss also creates a global economic burden estimated at over US$400 billion per year through healthcare expenses and lost productivity.
In these diseases, the retina's photoreceptor cells, which detect incoming light, gradually deteriorate and die. Yet much of the neural circuitry deeper within the retina can remain intact and capable of functioning. The problem is that, without photoreceptors, these surviving cells no longer receive the light signals needed to send visual information toward the brain.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in